

Release of Shares from Voluntary Escrow

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company"), today advises that in accordance with Listing Rule 3.10A, 649,351 fully paid ordinary shares ("Shares") will be released from voluntary escrow on 22 July 2024.

The shares which are the subject of this notice were issued on 22 January 2024. For further information, please refer to the Appendix 2A released by the Company on 22 January 2024.

Following the expiry of escrow restrictions on the above securities, the Company will have no further securities subject to escrow restrictions.

Authority

This announcement has been authorised for release by the Executive Director of Neurotech International Limited.

Investors:

Dr Thomas Duthy
Executive Director
td@neurotechinternational.com
+61 (0)402 493 727

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.